Sevicontrol-1: Efficacy and safety of a fixed combination of olmesartan 40 mg / amlodipine 10 mg in patients with insufficiently controlled hypertension under monotherapy with candesartan 32 mg - an open phase IIIb trial.[SEVICONTROL-1:Wirksamkeit und Sicherheit einer Fixkombination Olmesartan 40 mg / Amlodipin 10 mg bei Patienten mit einer unter Candesartan 32 mg Monotherapie unzureichend kontrollierter moderater essentieller Hypertonie – eine offene Phase IIIb – Studie]

Trial Profile

Sevicontrol-1: Efficacy and safety of a fixed combination of olmesartan 40 mg / amlodipine 10 mg in patients with insufficiently controlled hypertension under monotherapy with candesartan 32 mg - an open phase IIIb trial.[SEVICONTROL-1:Wirksamkeit und Sicherheit einer Fixkombination Olmesartan 40 mg / Amlodipin 10 mg bei Patienten mit einer unter Candesartan 32 mg Monotherapie unzureichend kontrollierter moderater essentieller Hypertonie – eine offene Phase IIIb – Studie]

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary) ; Candesartan cilexetil
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms Sevicontrol-1
  • Most Recent Events

    • 25 Sep 2012 Status changed from active, no longer recruiting to completed as reported by German Clinical Trials Register.
    • 01 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by German Clinical Trials Register.
    • 27 Jul 2012 Drug company (Daiichi Sankyo) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top